Alcon Acquires Aerie Pharmaceuticals

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

Alkermes plc Acquires Avadel Pharmaceuticals plc

February 12, 2026

Pharmaceuticals

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

Alcon Acquires Ivantis, Inc.

January 10, 2022

Medical Devices

Alcon has completed its acquisition of Ivantis, Inc., the developer of the Hydrus Microstent, integrating Ivantis’ manufacturing and sales employees to expand Alcon’s global surgical ophthalmology portfolio. Alcon said it will leverage its global footprint to broaden Hydrus Microstent availability and continue clinical research, including pursuing stand‑alone surgery indications in the U.S.

Danaher Acquires Aldevron for $9.6 Billion

June 17, 2021

Biotechnology

Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.

Novartis Acquires Gyroscope Therapeutics

December 22, 2021

Biotechnology

Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.

Alora Pharmaceuticals Acquires Osmotica's Legacy U.S. Business

August 30, 2021

Pharmaceuticals

Alora Pharmaceuticals, LLC closed the acquisition of Osmotica Pharmaceuticals plc's legacy U.S. business (including Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC) and the Marietta, Georgia manufacturing facility on August 27, 2021. Osmotica received approximately $111 million in proceeds, which it said would be used to retire a substantial portion of outstanding debt and to focus the company on its ophthalmic product UPNEEQ.